ESC Premium Access

Empagliflozin, a SGLT2 inhibitor, attenuates endothelial dysfunction and atherogenesis by inhibiting inflammatory responses in the vasculature and adipose tissue in diabetic apolipoprotein E-deficient

Topic: Atherosclerosis, Cerebrovascular Diseases, Aneurysm, Restenosis

Congress Presentation

About the speaker

Doctor Byambasuren Ganbaatar

Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima (Japan)
0 follower

6 more presentations in this session

Microcirculation injury is involved in anthracycline-induced cardiac toxicity

Speaker: Mr C. Galan (Madrid, ES)


Coronary vulnerable plaque development is promoted by multidirectional wall shear stress

Speaker: Mrs A. Hoogendoorn (Adelaide, AU)


Tyrosine kinase inhibitor nilotinib increases atherosclerosis burden in ApoE knock-out mice

Speaker: Doctor G. Detriche (Paris, FR)


The oral administration of colchicine prevents the progression of aortic aneurysm

Speaker: Doctor H. Okawa (Nagoya, JP)


Functional deficiency in activating fcgamma receptor protects against aortic abdominal aneurysm in mice

Speaker: Ms L. Lopez Sanz (Madrid, ES)


Access the full session

Vascular remodelling from capillaries to aorta

Speakers: Doctor B. Ganbaatar, Mr C. Galan, Mrs A. Hoogendoorn, Doctor G. Detriche, Doctor H. Okawa...

About the event


ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb